+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cimzia

  • ID: 4775195
  • Report
  • 65 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Cimzia (certolizumab; UCB/Astellas [also marketed by Dermira in some approved indications]) is a PEGylated humanized monoclonal antibody fragment, with high affinity for both soluble and membrane-bound tumor necrosis factor alpha. Celltech (now UCB) used its proprietary fragments of antibody (FAb) technology to develop Cimzia for use in chronic inflammatory diseases.

Cimzia was originally approved and launched in the US for the treatment of Crohn’s disease in April 2008. In October 2013, the US Food and Drug Administration approved Cimzia for the treatment of adult patients with active ankylosing spondylitis (AS). In the same month, the drug was granted approval in the EU for the treatment of adults with severe active axial spondyloarthritis, comprising severe active AS and severe active non-radiographic axial spondyloarthritis. Cimzia is also indicated for the treatment of rheumatoid arthritis and psoriatic arthritis.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Cimzia: Crohn's disease
Cimzia: Axial spondyloarthritis (axSpA)
Cimzia: Rheumatoid arthritis (RA)
Cimzia: Psoriatic arthritis (PsA)
Cimzia: Psoriasis

LIST OF FIGURES
Figure 39: Filgotinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 38: The authors drug assessment summary of ozanimod in Crohn’s disease
Figure 4: Sales of Stelara, key branded anti-TNFs, and Entyvio across the US, Japan, and five major EU markets, by drug, 2016–25
Figure 39: Ozanimod sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 42: Risankizumab for Crohn’s disease – SWOT analysis
Figure 43: The authors drug assessment summary of risankizumab in Crohn’s disease
Figure 40: The authors drug assessment summary of risankizumab in Crohn’s disease
Figure 7: Price sources and calculations, by country
Figure 44: Risankizumab sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 10: Cimzia for psoriatic arthritis – SWOT analysis
Figure 47: The authors drug assessment summary of upadacitinib in Crohn’s disease
Figure 10: Cimzia for Crohn’s disease – SWOT analysis

LIST OF TABLES
Table 1: Cimzia drug profile
Table 2: Cimzia pivotal trial data in Crohn’s disease
Table 3: Cimzia late-phase trial data in Crohn’s disease
Table 4: Cimzia sales for Crohn’s disease across the US, Japan, and Spain, by country ($m), 2016–25
Table 5: Cimzia drug profile
Table 6: Cimzia pivotal trial data in axial spondyloarthritis
Table 7: Cimzia ongoing late-phase trial in axial spondyloarthritis
Table 8: Cimzia drug profile
Table 9: Cimzia pivotal trial data in rheumatoid arthritis
Table 10: Cimzia late-phase trial data in rheumatoid arthritis
Table 11: Cimzia drug profile
Table 12: Cimzia pivotal trial data in psoriatic arthritis
Table 13: Cimzia drug profile
Figure 44: Upadacitinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Order Online - visit: https://www.researchandmarkets.com/reports/4775195
Adroll
adroll